nodes	percent_of_prediction	percent_of_DWPC	metapath
Gatifloxacin—Corneal disorder—Capecitabine—esophageal cancer	0.0543	0.0572	CcSEcCtD
Gatifloxacin—Keratoconjunctivitis—Capecitabine—esophageal cancer	0.0343	0.0361	CcSEcCtD
Gatifloxacin—Punctate keratitis—Capecitabine—esophageal cancer	0.0248	0.0261	CcSEcCtD
Gatifloxacin—Panic attack—Capecitabine—esophageal cancer	0.0168	0.0177	CcSEcCtD
Gatifloxacin—Generalised oedema—Cisplatin—esophageal cancer	0.0143	0.015	CcSEcCtD
Gatifloxacin—Sparfloxacin—ABCC2—esophageal cancer	0.0127	0.252	CrCbGaD
Gatifloxacin—Sneezing—Capecitabine—esophageal cancer	0.0113	0.0119	CcSEcCtD
Gatifloxacin—Visual acuity reduced—Capecitabine—esophageal cancer	0.0105	0.0111	CcSEcCtD
Gatifloxacin—Rhinorrhoea—Cisplatin—esophageal cancer	0.0105	0.011	CcSEcCtD
Gatifloxacin—Ageusia—Cisplatin—esophageal cancer	0.0105	0.011	CcSEcCtD
Gatifloxacin—Lomefloxacin—ABCC2—esophageal cancer	0.0105	0.207	CrCbGaD
Gatifloxacin—Infection—Carboplatin—esophageal cancer	0.0103	0.0108	CcSEcCtD
Gatifloxacin—Oral candidiasis—Capecitabine—esophageal cancer	0.00985	0.0104	CcSEcCtD
Gatifloxacin—Keratitis—Capecitabine—esophageal cancer	0.00965	0.0102	CcSEcCtD
Gatifloxacin—Haematemesis—Capecitabine—esophageal cancer	0.00901	0.00949	CcSEcCtD
Gatifloxacin—Ofloxacin—ABCC2—esophageal cancer	0.00895	0.177	CrCbGaD
Gatifloxacin—Torsade de pointes—Capecitabine—esophageal cancer	0.00893	0.0094	CcSEcCtD
Gatifloxacin—Metrorrhagia—Capecitabine—esophageal cancer	0.00876	0.00923	CcSEcCtD
Gatifloxacin—Throat sore—Capecitabine—esophageal cancer	0.00868	0.00915	CcSEcCtD
Gatifloxacin—Oropharyngeal discomfort—Capecitabine—esophageal cancer	0.00861	0.00906	CcSEcCtD
Gatifloxacin—Tongue disorder—Capecitabine—esophageal cancer	0.00861	0.00906	CcSEcCtD
Gatifloxacin—Body temperature increased—Carboplatin—esophageal cancer	0.00817	0.0086	CcSEcCtD
Gatifloxacin—Fluid retention—Cisplatin—esophageal cancer	0.00806	0.00849	CcSEcCtD
Gatifloxacin—Hyperaesthesia—Capecitabine—esophageal cancer	0.00798	0.0084	CcSEcCtD
Gatifloxacin—Rhinorrhoea—Capecitabine—esophageal cancer	0.00773	0.00814	CcSEcCtD
Gatifloxacin—Ageusia—Capecitabine—esophageal cancer	0.00773	0.00814	CcSEcCtD
Gatifloxacin—Eye irritation—Capecitabine—esophageal cancer	0.00733	0.00772	CcSEcCtD
Gatifloxacin—Norfloxacin—CYP2A6—esophageal cancer	0.00717	0.142	CrCbGaD
Gatifloxacin—Rectal haemorrhage—Capecitabine—esophageal cancer	0.00693	0.0073	CcSEcCtD
Gatifloxacin—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00688	0.00725	CcSEcCtD
Gatifloxacin—Lacrimation increased—Capecitabine—esophageal cancer	0.00679	0.00715	CcSEcCtD
Gatifloxacin—Haematemesis—Methotrexate—esophageal cancer	0.00671	0.00706	CcSEcCtD
Gatifloxacin—Renal failure acute—Cisplatin—esophageal cancer	0.00668	0.00703	CcSEcCtD
Gatifloxacin—Cyanosis—Methotrexate—esophageal cancer	0.00658	0.00693	CcSEcCtD
Gatifloxacin—Bone pain—Capecitabine—esophageal cancer	0.00653	0.00688	CcSEcCtD
Gatifloxacin—Neck pain—Capecitabine—esophageal cancer	0.00634	0.00667	CcSEcCtD
Gatifloxacin—Injection site reaction—Capecitabine—esophageal cancer	0.00622	0.00655	CcSEcCtD
Gatifloxacin—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.00616	0.00649	CcSEcCtD
Gatifloxacin—Colitis—Capecitabine—esophageal cancer	0.00601	0.00633	CcSEcCtD
Gatifloxacin—Candida infection—Capecitabine—esophageal cancer	0.00598	0.00629	CcSEcCtD
Gatifloxacin—Face oedema—Cisplatin—esophageal cancer	0.00595	0.00627	CcSEcCtD
Gatifloxacin—Fluid retention—Capecitabine—esophageal cancer	0.00594	0.00626	CcSEcCtD
Gatifloxacin—Gingivitis—Methotrexate—esophageal cancer	0.00594	0.00625	CcSEcCtD
Gatifloxacin—Dry eye—Capecitabine—esophageal cancer	0.00578	0.00609	CcSEcCtD
Gatifloxacin—Ecchymosis—Capecitabine—esophageal cancer	0.00566	0.00596	CcSEcCtD
Gatifloxacin—Mouth ulceration—Capecitabine—esophageal cancer	0.00566	0.00596	CcSEcCtD
Gatifloxacin—Nasopharyngitis—Cisplatin—esophageal cancer	0.00551	0.00581	CcSEcCtD
Gatifloxacin—Abnormal vision—Capecitabine—esophageal cancer	0.00546	0.00575	CcSEcCtD
Gatifloxacin—Mental disability—Capecitabine—esophageal cancer	0.00543	0.00572	CcSEcCtD
Gatifloxacin—Ear pain—Capecitabine—esophageal cancer	0.00533	0.00561	CcSEcCtD
Gatifloxacin—Diabetes mellitus—Capecitabine—esophageal cancer	0.00522	0.0055	CcSEcCtD
Gatifloxacin—Pancreatitis—Cisplatin—esophageal cancer	0.00522	0.0055	CcSEcCtD
Gatifloxacin—Photosensitivity—Capecitabine—esophageal cancer	0.00517	0.00545	CcSEcCtD
Gatifloxacin—Glossitis—Methotrexate—esophageal cancer	0.00506	0.00533	CcSEcCtD
Gatifloxacin—Eye pain—Capecitabine—esophageal cancer	0.00503	0.0053	CcSEcCtD
Gatifloxacin—Renal failure acute—Capecitabine—esophageal cancer	0.00492	0.00518	CcSEcCtD
Gatifloxacin—Thirst—Capecitabine—esophageal cancer	0.00477	0.00503	CcSEcCtD
Gatifloxacin—Renal impairment—Capecitabine—esophageal cancer	0.00477	0.00503	CcSEcCtD
Gatifloxacin—Dermatitis bullous—Capecitabine—esophageal cancer	0.00475	0.00501	CcSEcCtD
Gatifloxacin—Sparfloxacin—ABCB1—esophageal cancer	0.00468	0.0927	CrCbGaD
Gatifloxacin—Arthritis—Capecitabine—esophageal cancer	0.00468	0.00492	CcSEcCtD
Gatifloxacin—Vaginal inflammation—Methotrexate—esophageal cancer	0.00466	0.00491	CcSEcCtD
Gatifloxacin—Stomatitis—Cisplatin—esophageal cancer	0.00463	0.00488	CcSEcCtD
Gatifloxacin—Conjunctivitis—Cisplatin—esophageal cancer	0.00462	0.00486	CcSEcCtD
Gatifloxacin—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00454	0.00479	CcSEcCtD
Gatifloxacin—Migraine—Capecitabine—esophageal cancer	0.00447	0.00471	CcSEcCtD
Gatifloxacin—Vaginal infection—Methotrexate—esophageal cancer	0.0044	0.00463	CcSEcCtD
Gatifloxacin—Face oedema—Capecitabine—esophageal cancer	0.00439	0.00462	CcSEcCtD
Gatifloxacin—Bradycardia—Cisplatin—esophageal cancer	0.00434	0.00457	CcSEcCtD
Gatifloxacin—Ataxia—Capecitabine—esophageal cancer	0.00427	0.0045	CcSEcCtD
Gatifloxacin—Mouth ulceration—Methotrexate—esophageal cancer	0.00421	0.00444	CcSEcCtD
Gatifloxacin—Ecchymosis—Methotrexate—esophageal cancer	0.00421	0.00444	CcSEcCtD
Gatifloxacin—Dry skin—Capecitabine—esophageal cancer	0.00417	0.00439	CcSEcCtD
Gatifloxacin—Visual impairment—Cisplatin—esophageal cancer	0.00411	0.00433	CcSEcCtD
Gatifloxacin—Nasopharyngitis—Capecitabine—esophageal cancer	0.00406	0.00428	CcSEcCtD
Gatifloxacin—Gastritis—Capecitabine—esophageal cancer	0.00402	0.00424	CcSEcCtD
Gatifloxacin—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00401	0.00422	CcSEcCtD
Gatifloxacin—Muscular weakness—Capecitabine—esophageal cancer	0.00401	0.00422	CcSEcCtD
Gatifloxacin—Eye disorder—Cisplatin—esophageal cancer	0.00399	0.0042	CcSEcCtD
Gatifloxacin—Tinnitus—Cisplatin—esophageal cancer	0.00398	0.00419	CcSEcCtD
Gatifloxacin—Lymphadenopathy—Methotrexate—esophageal cancer	0.00396	0.00418	CcSEcCtD
Gatifloxacin—Asthma—Capecitabine—esophageal cancer	0.00393	0.00414	CcSEcCtD
Gatifloxacin—Dysphagia—Capecitabine—esophageal cancer	0.00393	0.00414	CcSEcCtD
Gatifloxacin—Diabetes mellitus—Methotrexate—esophageal cancer	0.00389	0.0041	CcSEcCtD
Gatifloxacin—Bronchospasm—Capecitabine—esophageal cancer	0.00386	0.00407	CcSEcCtD
Gatifloxacin—Photosensitivity—Methotrexate—esophageal cancer	0.00385	0.00406	CcSEcCtD
Gatifloxacin—Erythema—Cisplatin—esophageal cancer	0.00371	0.00391	CcSEcCtD
Gatifloxacin—Neutropenia—Capecitabine—esophageal cancer	0.00367	0.00387	CcSEcCtD
Gatifloxacin—Dysuria—Capecitabine—esophageal cancer	0.00367	0.00387	CcSEcCtD
Gatifloxacin—Renal failure acute—Methotrexate—esophageal cancer	0.00366	0.00386	CcSEcCtD
Gatifloxacin—Flatulence—Cisplatin—esophageal cancer	0.00366	0.00385	CcSEcCtD
Gatifloxacin—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00358	0.00378	CcSEcCtD
Gatifloxacin—Muscle spasms—Cisplatin—esophageal cancer	0.00357	0.00376	CcSEcCtD
Gatifloxacin—Hyperglycaemia—Capecitabine—esophageal cancer	0.00354	0.00373	CcSEcCtD
Gatifloxacin—Vision blurred—Cisplatin—esophageal cancer	0.0035	0.00368	CcSEcCtD
Gatifloxacin—Tremor—Cisplatin—esophageal cancer	0.00348	0.00366	CcSEcCtD
Gatifloxacin—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00347	0.00366	CcSEcCtD
Gatifloxacin—Stomatitis—Capecitabine—esophageal cancer	0.00341	0.00359	CcSEcCtD
Gatifloxacin—Conjunctivitis—Capecitabine—esophageal cancer	0.0034	0.00358	CcSEcCtD
Gatifloxacin—Haematuria—Capecitabine—esophageal cancer	0.00334	0.00352	CcSEcCtD
Gatifloxacin—Epistaxis—Capecitabine—esophageal cancer	0.0033	0.00348	CcSEcCtD
Gatifloxacin—Levofloxacin—ABCB1—esophageal cancer	0.00329	0.0652	CrCbGaD
Gatifloxacin—Convulsion—Cisplatin—esophageal cancer	0.00322	0.00339	CcSEcCtD
Gatifloxacin—Bradycardia—Capecitabine—esophageal cancer	0.0032	0.00337	CcSEcCtD
Gatifloxacin—Ataxia—Methotrexate—esophageal cancer	0.00318	0.00335	CcSEcCtD
Gatifloxacin—Ciprofloxacin—ABCB1—esophageal cancer	0.00318	0.063	CrCbGaD
Gatifloxacin—Myalgia—Cisplatin—esophageal cancer	0.00316	0.00333	CcSEcCtD
Gatifloxacin—Anxiety—Cisplatin—esophageal cancer	0.00315	0.00332	CcSEcCtD
Gatifloxacin—Hepatitis—Capecitabine—esophageal cancer	0.00314	0.00331	CcSEcCtD
Gatifloxacin—Pharyngitis—Capecitabine—esophageal cancer	0.00312	0.00329	CcSEcCtD
Gatifloxacin—Oedema peripheral—Capecitabine—esophageal cancer	0.0031	0.00326	CcSEcCtD
Gatifloxacin—Anaphylactic shock—Cisplatin—esophageal cancer	0.00303	0.00319	CcSEcCtD
Gatifloxacin—Oedema—Cisplatin—esophageal cancer	0.00303	0.00319	CcSEcCtD
Gatifloxacin—Visual impairment—Capecitabine—esophageal cancer	0.00303	0.00319	CcSEcCtD
Gatifloxacin—Infection—Cisplatin—esophageal cancer	0.00301	0.00317	CcSEcCtD
Gatifloxacin—Erythema multiforme—Capecitabine—esophageal cancer	0.00297	0.00313	CcSEcCtD
Gatifloxacin—Thrombocytopenia—Cisplatin—esophageal cancer	0.00297	0.00312	CcSEcCtD
Gatifloxacin—Tachycardia—Cisplatin—esophageal cancer	0.00296	0.00311	CcSEcCtD
Gatifloxacin—Eye disorder—Capecitabine—esophageal cancer	0.00294	0.00309	CcSEcCtD
Gatifloxacin—Tinnitus—Capecitabine—esophageal cancer	0.00293	0.00309	CcSEcCtD
Gatifloxacin—Hyperhidrosis—Cisplatin—esophageal cancer	0.00293	0.00308	CcSEcCtD
Gatifloxacin—Asthma—Methotrexate—esophageal cancer	0.00292	0.00308	CcSEcCtD
Gatifloxacin—Anorexia—Cisplatin—esophageal cancer	0.00289	0.00304	CcSEcCtD
Gatifloxacin—Pancreatitis—Methotrexate—esophageal cancer	0.00287	0.00302	CcSEcCtD
Gatifloxacin—Hypotension—Cisplatin—esophageal cancer	0.00283	0.00298	CcSEcCtD
Gatifloxacin—Chills—Capecitabine—esophageal cancer	0.00282	0.00297	CcSEcCtD
Gatifloxacin—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00276	0.00291	CcSEcCtD
Gatifloxacin—Erythema—Capecitabine—esophageal cancer	0.00274	0.00288	CcSEcCtD
Gatifloxacin—Dysuria—Methotrexate—esophageal cancer	0.00273	0.00288	CcSEcCtD
Gatifloxacin—Neutropenia—Methotrexate—esophageal cancer	0.00273	0.00288	CcSEcCtD
Gatifloxacin—Paraesthesia—Cisplatin—esophageal cancer	0.00272	0.00287	CcSEcCtD
Gatifloxacin—Dyspnoea—Cisplatin—esophageal cancer	0.0027	0.00284	CcSEcCtD
Gatifloxacin—Flatulence—Capecitabine—esophageal cancer	0.0027	0.00284	CcSEcCtD
Gatifloxacin—Dysgeusia—Capecitabine—esophageal cancer	0.00268	0.00282	CcSEcCtD
Gatifloxacin—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00267	0.00281	CcSEcCtD
Gatifloxacin—Back pain—Capecitabine—esophageal cancer	0.00265	0.00279	CcSEcCtD
Gatifloxacin—Decreased appetite—Cisplatin—esophageal cancer	0.00263	0.00277	CcSEcCtD
Gatifloxacin—Muscle spasms—Capecitabine—esophageal cancer	0.00263	0.00277	CcSEcCtD
Gatifloxacin—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00258	0.00272	CcSEcCtD
Gatifloxacin—Vision blurred—Capecitabine—esophageal cancer	0.00258	0.00272	CcSEcCtD
Gatifloxacin—Tremor—Capecitabine—esophageal cancer	0.00256	0.0027	CcSEcCtD
Gatifloxacin—Stomatitis—Methotrexate—esophageal cancer	0.00254	0.00268	CcSEcCtD
Gatifloxacin—Conjunctivitis—Methotrexate—esophageal cancer	0.00253	0.00267	CcSEcCtD
Gatifloxacin—Sweating—Methotrexate—esophageal cancer	0.0025	0.00263	CcSEcCtD
Gatifloxacin—Feeling abnormal—Cisplatin—esophageal cancer	0.0025	0.00263	CcSEcCtD
Gatifloxacin—Haematuria—Methotrexate—esophageal cancer	0.00249	0.00262	CcSEcCtD
Gatifloxacin—Epistaxis—Methotrexate—esophageal cancer	0.00246	0.00259	CcSEcCtD
Gatifloxacin—Vertigo—Capecitabine—esophageal cancer	0.00246	0.00259	CcSEcCtD
Gatifloxacin—Syncope—Capecitabine—esophageal cancer	0.00245	0.00258	CcSEcCtD
Gatifloxacin—Palpitations—Capecitabine—esophageal cancer	0.00242	0.00255	CcSEcCtD
Gatifloxacin—Loss of consciousness—Capecitabine—esophageal cancer	0.00241	0.00253	CcSEcCtD
Gatifloxacin—Body temperature increased—Cisplatin—esophageal cancer	0.0024	0.00252	CcSEcCtD
Gatifloxacin—Hypertension—Capecitabine—esophageal cancer	0.00236	0.00249	CcSEcCtD
Gatifloxacin—Hepatitis—Methotrexate—esophageal cancer	0.00234	0.00246	CcSEcCtD
Gatifloxacin—Myalgia—Capecitabine—esophageal cancer	0.00233	0.00245	CcSEcCtD
Gatifloxacin—Arthralgia—Capecitabine—esophageal cancer	0.00233	0.00245	CcSEcCtD
Gatifloxacin—Chest pain—Capecitabine—esophageal cancer	0.00233	0.00245	CcSEcCtD
Gatifloxacin—Pharyngitis—Methotrexate—esophageal cancer	0.00232	0.00245	CcSEcCtD
Gatifloxacin—Anxiety—Capecitabine—esophageal cancer	0.00232	0.00245	CcSEcCtD
Gatifloxacin—Visual impairment—Methotrexate—esophageal cancer	0.00226	0.00237	CcSEcCtD
Gatifloxacin—Confusional state—Capecitabine—esophageal cancer	0.00225	0.00237	CcSEcCtD
Gatifloxacin—Oedema—Capecitabine—esophageal cancer	0.00223	0.00235	CcSEcCtD
Gatifloxacin—Hypersensitivity—Cisplatin—esophageal cancer	0.00223	0.00235	CcSEcCtD
Gatifloxacin—Infection—Capecitabine—esophageal cancer	0.00222	0.00234	CcSEcCtD
Gatifloxacin—Erythema multiforme—Methotrexate—esophageal cancer	0.00221	0.00233	CcSEcCtD
Gatifloxacin—Shock—Capecitabine—esophageal cancer	0.0022	0.00231	CcSEcCtD
Gatifloxacin—Eye disorder—Methotrexate—esophageal cancer	0.00219	0.0023	CcSEcCtD
Gatifloxacin—Thrombocytopenia—Capecitabine—esophageal cancer	0.00219	0.0023	CcSEcCtD
Gatifloxacin—Tinnitus—Methotrexate—esophageal cancer	0.00218	0.0023	CcSEcCtD
Gatifloxacin—Tachycardia—Capecitabine—esophageal cancer	0.00218	0.0023	CcSEcCtD
Gatifloxacin—Asthenia—Cisplatin—esophageal cancer	0.00217	0.00229	CcSEcCtD
Gatifloxacin—Hyperhidrosis—Capecitabine—esophageal cancer	0.00216	0.00227	CcSEcCtD
Gatifloxacin—Anorexia—Capecitabine—esophageal cancer	0.00213	0.00224	CcSEcCtD
Gatifloxacin—Chills—Methotrexate—esophageal cancer	0.0021	0.00221	CcSEcCtD
Gatifloxacin—Hypotension—Capecitabine—esophageal cancer	0.00209	0.0022	CcSEcCtD
Gatifloxacin—Diarrhoea—Cisplatin—esophageal cancer	0.00207	0.00218	CcSEcCtD
Gatifloxacin—Erythema—Methotrexate—esophageal cancer	0.00204	0.00215	CcSEcCtD
Gatifloxacin—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00203	0.00214	CcSEcCtD
Gatifloxacin—Insomnia—Capecitabine—esophageal cancer	0.00202	0.00213	CcSEcCtD
Gatifloxacin—Paraesthesia—Capecitabine—esophageal cancer	0.00201	0.00211	CcSEcCtD
Gatifloxacin—Dysgeusia—Methotrexate—esophageal cancer	0.00199	0.0021	CcSEcCtD
Gatifloxacin—Dyspnoea—Capecitabine—esophageal cancer	0.00199	0.0021	CcSEcCtD
Gatifloxacin—Back pain—Methotrexate—esophageal cancer	0.00197	0.00208	CcSEcCtD
Gatifloxacin—Dyspepsia—Capecitabine—esophageal cancer	0.00197	0.00207	CcSEcCtD
Gatifloxacin—Decreased appetite—Capecitabine—esophageal cancer	0.00194	0.00204	CcSEcCtD
Gatifloxacin—Vomiting—Cisplatin—esophageal cancer	0.00193	0.00203	CcSEcCtD
Gatifloxacin—Vision blurred—Methotrexate—esophageal cancer	0.00192	0.00202	CcSEcCtD
Gatifloxacin—Rash—Cisplatin—esophageal cancer	0.00191	0.00201	CcSEcCtD
Gatifloxacin—Constipation—Capecitabine—esophageal cancer	0.00191	0.00201	CcSEcCtD
Gatifloxacin—Dermatitis—Cisplatin—esophageal cancer	0.00191	0.00201	CcSEcCtD
Gatifloxacin—Feeling abnormal—Capecitabine—esophageal cancer	0.00184	0.00194	CcSEcCtD
Gatifloxacin—Vertigo—Methotrexate—esophageal cancer	0.00183	0.00193	CcSEcCtD
Gatifloxacin—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00183	0.00192	CcSEcCtD
Gatifloxacin—Nausea—Cisplatin—esophageal cancer	0.0018	0.0019	CcSEcCtD
Gatifloxacin—Urticaria—Capecitabine—esophageal cancer	0.00177	0.00187	CcSEcCtD
Gatifloxacin—Abdominal pain—Capecitabine—esophageal cancer	0.00177	0.00186	CcSEcCtD
Gatifloxacin—Body temperature increased—Capecitabine—esophageal cancer	0.00177	0.00186	CcSEcCtD
Gatifloxacin—Convulsion—Methotrexate—esophageal cancer	0.00177	0.00186	CcSEcCtD
Gatifloxacin—Chest pain—Methotrexate—esophageal cancer	0.00173	0.00183	CcSEcCtD
Gatifloxacin—Myalgia—Methotrexate—esophageal cancer	0.00173	0.00183	CcSEcCtD
Gatifloxacin—Arthralgia—Methotrexate—esophageal cancer	0.00173	0.00183	CcSEcCtD
Gatifloxacin—Confusional state—Methotrexate—esophageal cancer	0.00168	0.00177	CcSEcCtD
Gatifloxacin—Anaphylactic shock—Methotrexate—esophageal cancer	0.00166	0.00175	CcSEcCtD
Gatifloxacin—Infection—Methotrexate—esophageal cancer	0.00165	0.00174	CcSEcCtD
Gatifloxacin—Hypersensitivity—Capecitabine—esophageal cancer	0.00165	0.00173	CcSEcCtD
Gatifloxacin—Thrombocytopenia—Methotrexate—esophageal cancer	0.00163	0.00171	CcSEcCtD
Gatifloxacin—Hyperhidrosis—Methotrexate—esophageal cancer	0.00161	0.00169	CcSEcCtD
Gatifloxacin—Asthenia—Capecitabine—esophageal cancer	0.0016	0.00169	CcSEcCtD
Gatifloxacin—Anorexia—Methotrexate—esophageal cancer	0.00158	0.00167	CcSEcCtD
Gatifloxacin—Pruritus—Capecitabine—esophageal cancer	0.00158	0.00166	CcSEcCtD
Gatifloxacin—Hypotension—Methotrexate—esophageal cancer	0.00155	0.00164	CcSEcCtD
Gatifloxacin—Diarrhoea—Capecitabine—esophageal cancer	0.00153	0.00161	CcSEcCtD
Gatifloxacin—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00151	0.0016	CcSEcCtD
Gatifloxacin—Insomnia—Methotrexate—esophageal cancer	0.0015	0.00158	CcSEcCtD
Gatifloxacin—Paraesthesia—Methotrexate—esophageal cancer	0.00149	0.00157	CcSEcCtD
Gatifloxacin—Dyspnoea—Methotrexate—esophageal cancer	0.00148	0.00156	CcSEcCtD
Gatifloxacin—Somnolence—Methotrexate—esophageal cancer	0.00148	0.00156	CcSEcCtD
Gatifloxacin—Dizziness—Capecitabine—esophageal cancer	0.00148	0.00156	CcSEcCtD
Gatifloxacin—Dyspepsia—Methotrexate—esophageal cancer	0.00146	0.00154	CcSEcCtD
Gatifloxacin—Decreased appetite—Methotrexate—esophageal cancer	0.00145	0.00152	CcSEcCtD
Gatifloxacin—Vomiting—Capecitabine—esophageal cancer	0.00142	0.0015	CcSEcCtD
Gatifloxacin—Rash—Capecitabine—esophageal cancer	0.00141	0.00148	CcSEcCtD
Gatifloxacin—Dermatitis—Capecitabine—esophageal cancer	0.00141	0.00148	CcSEcCtD
Gatifloxacin—Headache—Capecitabine—esophageal cancer	0.0014	0.00147	CcSEcCtD
Gatifloxacin—Feeling abnormal—Methotrexate—esophageal cancer	0.00137	0.00144	CcSEcCtD
Gatifloxacin—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00136	0.00143	CcSEcCtD
Gatifloxacin—Nausea—Capecitabine—esophageal cancer	0.00133	0.0014	CcSEcCtD
Gatifloxacin—Urticaria—Methotrexate—esophageal cancer	0.00132	0.00139	CcSEcCtD
Gatifloxacin—Abdominal pain—Methotrexate—esophageal cancer	0.00131	0.00138	CcSEcCtD
Gatifloxacin—Body temperature increased—Methotrexate—esophageal cancer	0.00131	0.00138	CcSEcCtD
Gatifloxacin—Hypersensitivity—Methotrexate—esophageal cancer	0.00122	0.00129	CcSEcCtD
Gatifloxacin—Asthenia—Methotrexate—esophageal cancer	0.00119	0.00126	CcSEcCtD
Gatifloxacin—Pruritus—Methotrexate—esophageal cancer	0.00118	0.00124	CcSEcCtD
Gatifloxacin—Diarrhoea—Methotrexate—esophageal cancer	0.00114	0.0012	CcSEcCtD
Gatifloxacin—Dizziness—Methotrexate—esophageal cancer	0.0011	0.00116	CcSEcCtD
Gatifloxacin—Vomiting—Methotrexate—esophageal cancer	0.00106	0.00111	CcSEcCtD
Gatifloxacin—Rash—Methotrexate—esophageal cancer	0.00105	0.0011	CcSEcCtD
Gatifloxacin—Dermatitis—Methotrexate—esophageal cancer	0.00105	0.0011	CcSEcCtD
Gatifloxacin—Headache—Methotrexate—esophageal cancer	0.00104	0.0011	CcSEcCtD
Gatifloxacin—Nausea—Methotrexate—esophageal cancer	0.000988	0.00104	CcSEcCtD
